行情

CRBP

CRBP

Corbus Pharms
NASDAQ

实时行情|Nasdaq Last Sale

5.74
+0.10
+1.77%
盘后: 5.76 +0.02 +0.35% 17:02 09/13 EDT
开盘
5.65
昨收
5.64
最高
5.79
最低
5.62
成交量
56.05万
成交额
--
52周最高
9.11
52周最低
4.800
市值
3.71亿
市盈率(TTM)
-6.0326
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CRBP 新闻

  • 绝不延迟脱欧 英首相自比"绿巨人":越疯狂,就越强大
  • 环球网.1小时前
  • 沙特石油设施遇袭产量减半 美随时准备动用石油储备
  • 新京报网.2小时前
  • 新华国际时评:央行“放水”恐难纾欧元区之困
  • 新华网.2小时前
  • 沙特官员:周一石油产量将恢复到正常水平
  • 新浪美股.3小时前

更多

所属板块

生物技术和医学研究
+0.20%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

CRBP 简况

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
展开

Webull提供Corbus Pharmaceuticals Holdings Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。